Abstract:Background Several studies have suggested that drug resistance in colon cancer patients with diabetes may be associated with long-term insulin administration, which in turn decreases the survival rate. Metformin is a commonly used drug to treat diabetes but has been recently demonstrated to have a potential therapeutic effect on colon cancer. This study aimed to elucidate the underlying mechanism by which metformin reverts insulin-induced oxaliplatin resistance in human colon cancer HCT116 cells. Methods Two colon cancer cell lines (HCT116 and LoVo) were used to verify whether the expression of insulin receptor substrate 1 (IRS-1) could impact the half maximal inhibitory concentration (IC50) of oxaliplatin after chronic insulin treatment. The IC50 of oxaliplatin in both cell lines was measured to identify metformin sensitization to oxaliplatin. The adenosine monophosphate-activated protein kinase (AMPK) inhibitor, namely AMPK small interfering RNA, was used to block AMPK activation to identify critical proteins in the AMPK/Erk signaling pathway. Bcl-2 is a vital antiapoptotic protein involved in the mitochondrial apoptosis pathway. Finally, immunofluorescence and electron microscopy were performed to investigate how metformin affects the ultrastructural integrity of mitochondria. Results The IC50 of oxaliplatin in HCT116 cells was noticeably increased. After the cells were treated with metformin, oxaliplatin resistance was reversed. According to the results of the western blotting assay of vital proteins involved in the classical apoptosis pathway, cleaved caspase-9 was noticeably upregulated, suggesting that the mitochondrial apoptosis pathway was activated. These results were verified by imaging of mitochondria using electron microscopy. The AMPK/Erk signaling pathway experiments revealed that the upregulation of Bcl-2 induced by insulin through Erk phosphorylation was inhibited by metformin and that such inhibition could be mitigated by the inhibition of AMPK. Conclusions Insulin-induced oxaliplatin resistance was reversed by metformin-mediated AMPK activation. Accordingly, metformin is likely to sensitize patients with diabetes to chemotherapeutic drugs used to treat colon cancer.

Sirt3 aggravates metformin-induced energy stress and apoptosis in ovarian cancer cells

Cytotoxicity of metformin against HT29 colon cancer cells contributes to mitochondrial Sirt3 upregulation

SIRT3 Participates in Glucose Metabolism Interruption and Apoptosis Induced by BH3 Mimetic S1 in Ovarian Cancer Cells.

Metformin activates AMPK/SIRT1/NF-κB pathway and induces mitochondrial dysfunction to drive caspase3/GSDME-mediated cancer cell pyroptosis

Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling

Metformin improves the sensitivity of ovarian cancer cells to chemotherapeutic agents.

Effect of metformin on the proliferation, apoptosis, invasion and autophagy of ovarian cancer cells.

Metformin Sensitizes Endometrial Cancer Cells to Chemotherapy Through IDH1-induced Nrf2 Expression Via an Epigenetic Mechanism

Metformin Revert Insulin‐induced Oxaliplatin Resistance by Activating Mitochondrial Apoptosis Pathway in Human Colon Cancer HCT116 Cells

Abstract 2856: Inhibition of Glycolysis Sensitizes Cancer Cells to Metformin-Induced Anoikis

Metformin Combined with Nelfinavir Induces SIRT3/mROS-dependent Autophagy in Human Cervical Cancer Cells and Xenograft in Nude Mice

Inhibiting ROS-TFE3-dependent Autophagy Enhances the Therapeutic Response to Metformin in Breast Cancer

Fibroblasts Rescue Oral Squamous Cancer Cell from Metformin-Induced Apoptosis Via Alleviating Metabolic Disbalance and Inhibiting AMPK Pathway

Metformin ameliorates insulin resistance in L6 rat skeletal muscle cells through upregulation of SIRT3

Metabolomics profiling of metformin-mediated metabolic reprogramming bypassing AMPKα

Metformin is Associated with Reduced Cell Proliferation in Human Endometrial Cancer by Inbibiting PI3K/AKT/mTOR Signaling.

Divergent Metabolic Effects of Metformin Merge to Enhance Eicosapentaenoic Acid Metabolism and Inhibit Ovarian Cancer In Vivo

Metformin Suppresses Self-Renewal Ability and Tumorigenicity of Osteosarcoma Stem Cells Via Reactive Oxygen Species-Mediated Apoptosis and Autophagy.

Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis

Metformin Attenuates Hepatoma Cell Proliferation by Decreasing Glycolytic Flux Through the HIF-1α/PFKFB3/PFK1 Pathway.

Integrin Β1-Mediated Cell–Cell Adhesion Augments Metformin-Induced Anoikis